- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00713635
Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome
The Prenatal Effects of Congenital Heart Disease on Neurodevelopmental Outcome
Przegląd badań
Status
Warunki
Szczegółowy opis
Congenital heart disease (CHD) is the most common class of birth defect and is a major cause of infant and child death and morbidity, including neurodevelopmental delay. Children with severe forms of CHD are at high risk for a spectrum of neurocognitive difficulties that include learning disability, attention deficit and hyperactivity disorder, behavioral problems and mental retardation. The etiology of neurodevelopmental delay in children with CHD is not fully understood but is thought to be secondary to a combination of pre- and post-natal insults to the brain. It has been observed that fetuses with severe forms of CHD have abnormal blood flow to the brain as measured by Doppler ultrasound. This "centralization" or redirection of blood flow toward vital organs such as the brain has been shown to lead to abnormal brain development in other fetal diseases, such as intrauterine growth restriction. Evidence of the importance of prenatal brain development in the setting of CHD is amounting. Neonates with complex CHD demonstrate abnormalities of brain structure and blood flow prior to cardiothoracic surgery. However, to date, associations between abnormal fetal brain blood flow and neonatal neurologic outcomes and brain function have not been established in the CHD population. Finally, newborns with CHD have been shown to have abnormalities in heart rate over a 24 hour period. This finding suggests that the autonomic nervous system, which controls heart rate and blood pressure, may not function properly in infants with CHD.
The study proposes that these changes in blood flows in the fetus with heart disease could be responsible in part for poor brain growth, abnormal brain structure and function and developmental delay in childhood. Investigators will use routine obstetrical ultrasound and fetal echocardiograms to evaluate blood flow to vital organs and brain growth in fetuses with CHD. Investigators will use non-invasive fetal monitors to measure fetal heart rate and movement. Investigators will look at brain structure using Magnetic Resonance Imaging (MRI) in the fetus and newborn. Afterbirth, investigators will use non-invasive monitors to measure neonatal heart rate and blood pressure changes in response to a tilt, similar to what is experienced when placing an infant in a car seat. Investigators will use a non-invasive monitor consisting of a sticker applied to the skin to measure the level of oxygen in the brain. Investigators will also measure brain function in the newborn with an electroencephalogram(EEG) that records the electrical signaling between different parts of the brain using a special plastic hat like a swim cap. Regular physical exams with a pediatrician to measure growth and development will take place. A special test designed to detect learning disabilities will also be done when the child is 14 months old. This test will consist of talking with the child, reading stories, and showing the child pictures and colors. There will be no extra blood tests needed and none of the tests pose any risk to the mother, fetus, infant, or child.
The possible benefits to the child and the family will be early identification of any brain abnormality in the newborn period as well as learning disabilities in the toddler which will then allow the child to receive therapies designed to treat these problems. Studies show that early identification and treatment of learning disabilities are important to enhance the potential of the child.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New York
-
New York, New York, Stany Zjednoczone, 10032
- Columbia University College of Physicians & Surgeons, Morgan Stanley Children's Hospital of New York
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- All women who present to Columbia University Medical Center between 18-24 wks gestational age with the following fetal diagnoses will be invited to participate:
- Hypoplastic Left Heart Syndrome (HLHS)
- Transposition of the Great Arteries (TGA)
- Tetralogy of Fallot (TOF)
- Lung anomalies consisting of either congenital cystic adenomatoid malformations or bronchogenic cysts
Exclusion Criteria:
- Documented fetal chromosomal anomaly
- Structural brain malformations
- Evidence of placental insufficiency or Intrauterine growth retardation
- Documented hydrops fetalis or sustained cardiac arrhythmias
- Anticipated delivery at an outside hospital
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
1
Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
|
|
2
Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
|
|
3
Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
|
|
4
Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Neurodevelopmental scores as measured by the Bayley Scales of Infant Development
Ramy czasowe: 18 months of age
|
18 months of age
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
|---|---|
|
Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG
Ramy czasowe: Neonatal EEG within 72 hours of birth
|
Neonatal EEG within 72 hours of birth
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Ramy czasowe: Fetal assessment between 18-24 wk GA
|
Fetal assessment between 18-24 wk GA
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Ramy czasowe: Fetal assessment between 28-32 wk GA
|
Fetal assessment between 28-32 wk GA
|
|
Neurologic Function as defined by fetal and neonatal autonomic nervous system assessments (fetal heart rate variability and movement coupling and neonatal tilt test)
Ramy czasowe: Fetal assessment between 34-38 wk GA
|
Fetal assessment between 34-38 wk GA
|
|
Neurologic Function as defined by neonatal electroencephalographic power and coherence as measured by a neonatal high-density EEG
Ramy czasowe: Neonatal EEG at 1 month of age
|
Neonatal EEG at 1 month of age
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Ismee A Williams, MD, MS, Columbia University
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- AAAD1879
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Wrodzona wada serca
-
Peking University Third HospitalJeszcze nie rekrutacjaCentral Compartment Atopic Disease (CCAD)Chiny
-
Region SkaneRejestracja na zaproszenieNiewydolność serca Klasa II według New York Heart Association (NYHA). | Niewydolność serca Klasa III według New York Heart Association (NYHA).Szwecja
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... i inni współpracownicyZakończonyNiewydolność serca, skurcz | Niewydolność serca ze zmniejszoną frakcją wyrzutową | Niewydolność serca Klasa IV według New York Heart Association | Niewydolność serca Klasa III według New York Heart AssociationPolska
-
University of WashingtonAmerican Heart AssociationZakończonyNiewydolność serca, zastoinowa | Zmiana mitochondrialna | Niewydolność serca Klasa IV według New York Heart AssociationStany Zjednoczone
-
Portuguese Association of Interventional CardiologyMedtronicRekrutacyjnyCiężkie objawowe zwężenie zastawki aortalnej (zdefiniowane jako klasa New York Heart Association (NYHA) ≥ II)Portugalia
-
Bambino Gesù Hospital and Research InstituteZakończonyCiężka otyłość dziecięca (BMI > 97° szt. -według wykresów BMI Centers for Disease Control and Prevention-) | Zmienione testy czynnościowe wątroby | Nietolerancja glikemicznaWłochy
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
-
Janssen Pharmaceutical K.K.ZakończonyOporna na leczenie Mycobacterium Avium Complex-lung Disease (MAC-LD)Tajwan, Japonia, Korea Południowa
-
Adelphi Values LLCBlueprint Medicines CorporationZakończonyBiałaczka z komórek tucznych (MCL) | Agresywna mastocytoza układowa (ASM) | SM w Assoc Clonal Hema Lineage Non-mast Cell Lineage Disease (SM-AHNMD) | Tląca się mastocytoza układowa (SSM) | Indolentna układowa mastocytoza (ISM) Podgrupa ISM w pełni zatrudnionaStany Zjednoczone